2025-521349-25-00
CTIS ↗
4D-150-C004
Macular neovascularization secondary to age-related macular degeneration (nAMD)
biotech · Choroideremia · X-Linked Retinitis Pigmentosa · FDMT
4D Molecular Therapeutics
4D Molecular Therapeutics trial registry — 20 ClinicalTrials.gov studies with program phase, status, and indication context.
5858 Horton St, 455, Emeryville, California 94608, US HQ
2013 Founded
213 Employees
Public company Type
FDMT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 5858 Horton St, 455, Emeryville, California 94608, US
- Founded
- 2013
- Employees
- 213
- Programs
- 19
- Drugs
- 13
- Patents
- 15
4D Molecular Therapeutics clinical trials
Registry index of 20 ClinicalTrials.gov studies linked to 4D Molecular Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.
4D Molecular Therapeutics trial registry — 20 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for 4D Molecular Therapeutics.
-
4D-150-C004 — Phase 3
Clinical update -
MRx0518 Capsules — Phase 1
Clinical update -
MRx-4DP0004 — Phase 2
Clinical update -
4D-150 IVT — Phase 2
Clinical update -
4D-150 IVT (3E10 vg/eye) — Phase 3
Clinical update -
4D-150 IVT (3E10 vg/eye) — Phase 3
Clinical update -
Training with 4D Motion Capture Device — Phase 1
Clinical update -
MRx0029 — Phase 1
Clinical update